Hope for Heavily Pretreated NSCLC is Provided by Novel ADC.

Published Date: 12 Sep 2023

A novel antibody-drug conjugate called HER3-DXd may provide meaningful and long-lasting responses in patients with EGFR-mutated NSCLC who have progressed after receiving multiple lines of therapy, according to new phase 2 data.

Read Full News

Latest News


News All Time

Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

Examines Office-Based Transperineal Prostate Biopsies Methodology.

2.

A global study demonstrates that screening for lung cancer significantly raises the long-term survival rate.

3.

Is a $2,000 Whole-Body MRI Worth It?

4.

Surgery may not be necessary to treat invasive breast cancer

5.

Limited Benefit from New Drugs; Significant Increase in Drug Prices; AI Boost for Mammo Results.


© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot